Cargando…

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children

OBJECTIVE: The aim of this study was to evaluate neurofilament light chain as blood biomarker for disease activity in children and adolescents with different types of spinal muscular atrophy (SMA) and establish pediatric reference values. METHODS: We measured neurofilament light chain levels in seru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitz, Elisa, Smitka, Martin, Schallner, Jens, Akgün, Katja, Ziemssen, Tjalf, von der Hagen, Maja, Tüngler, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528467/ https://www.ncbi.nlm.nih.gov/pubmed/34482646 http://dx.doi.org/10.1002/acn3.51449

Ejemplares similares

Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
por: Saak, Annika, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study
por: Li, Jin‐Yue, et al.
Publicado: (2023)

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
por: Nötzel, Martin, et al.
Publicado: (2022)

Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy
por: Spicer, Charlotte, et al.
Publicado: (2021)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019)

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series
por: Alves, Christiano R.R., et al.
Publicado: (2021)

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
por: Faravelli, Irene, et al.
Publicado: (2020)

Neurofilament Light Chain in Spinal Fluid and Plasma in Multiple System Atrophy – A Prospective, Longitudinal Biomarker Study
por: Singer, Wolfgang, et al.
Publicado: (2023)

Cerebellar atrophy on top of motor neuron compromise as indicator of late-onset GM2 gangliosidosis
por: Hölzer, Hans Thomas, et al.
Publicado: (2021)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not
por: Frank, Anika, et al.
Publicado: (2022)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS
por: Schneider, Ruth, et al.
Publicado: (2020)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Development of an age‐adjusted model for blood neurofilament light chain
por: Harp, Christopher, et al.
Publicado: (2022)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mtdkn5l6u473nlh1cnp7550mp9